Drink and Drugs News DDN Dec 2017 | Page 17

England and Wales are also at their highest ever. Meanwhile, Trump instructs his administration to use ‘all appropriate emergency and other authorities’ to respond to opioid crisis in the country, which has seen overdoses quadruple since the turn of the century. ‘Not coincidentally’ the level of opioid prescribing has quadrupled over the same period, points out the interim report from his own Commission on Combating Drug Addiction and the Opioid Crisis. purgatory. Release marks its 50th anniversary with a powerful pop-up exhibition, ‘The Museum of Drug Policy’, while Russell Brand’s interview with DDN proves divisive. All things NOVEL Global Drug Survey 2018 – the latest version of the world’s largest drug survey – has just been launched. Prof Adam Winstock asks for your help in assessing the new drugs on the block NOVEMBER SEPTEMBER Hot on the heels of last month’s bleak drug death figures and the King’s Fund’s worrying study from July, a report from the government’s own advisers, the ACMD, warns that funding cuts are now the single biggest threat to drug treatment recovery outcomes. A lack of spending on drug treatment is ‘short sighted and a catalyst for disaster,’ states its recovery committee chair, Annette Dale-Perera, while new figures from PHE map out the disproportionate impact problem drinking has on deprived communities. ‘We constantly need to be saying, “Is our service right? Is it fit for purpose?’” Haringey’s Sarah Hart says in our comprehensive look at the commissioning landscape. ‘And I’m not sure that without a tender process people would do that.’ To illustrate the ever-changing nature of the challenges she describes, the latest NDTMS figures show a 23 per cent increase in the number of people seeking treatment for crack, along with a 12 per cent increase in those presenting with combined crack and opiate problems. And Scotland’s minimum pricing plans finally get the go-ahead after five years of legal wrangles, as the UK Supreme Court’s ‘landmark’ ruling rejects the Scotch Whisky Association’s final appeal. DECEMBER OCTOBER The Welsh Government introduces a bill to create a minimum unit price for alcohol, despite the Scots’ attempts to do the same still languishing in legal www.drinkanddrugsnews.com As another year comes to an end, plans are well underway for the 11th annual DDN service user involvement conference, your chance to have your say on the future of the sector. See you on 22 February in Birmingham! Can you help us define and describe the new drugs on the block? Your experiences will help us to share information with others on what drugs are worth a mention, what’s best avoided and how to stay safe. With over 500 new drugs being identified in the last five years, we’re known for having our ear to the ground and learning, before others, about drugs that come onto the market. Our global drug survey helps us gain a unique understanding of new drugs: • form (eg pill, powder, liquid) • how people take it • what type of other drug it most resembles (eg cannabis, trips, stimulants, opioid) • how long it takes for the effects to come on • how long a single dose lasts • intensity of effect • positive and negative effects Most research on drugs is based on toxicological analyses, web scrapings of user forums and emergency department presentations, whereas our research come s straight from the horse’s mouth, so to speak. That’s 100,000 horses in fact; all sharing their personal stories with us, in depth and in their own way – something we’re really proud of. And since we started, we’ve produced some of the most highly cited papers on mephedrone, synthetic cannabinoids, DMT, the NBOMe series, methoxetamine and LSD analogues (and we have a new one on ayahausca coming soon). In previous years, drugs were designed to mimic cannabis (the synthetic cannabinoid receptor agonists or SCRAs) and stimulants (cathinones like mephedrone and methylone), however, last year we found that new drugs were commonly being produced to mimic psychedelics. With the rise of fentanyl analogues and other depressant drugs, GDS aims to get a better insight into how they are being used and who is using them. That way we can share information and help support people to stay safe. If you’ve tried a new drug in the last year and want to share your experiences and opinions anonymously, please take 15-30 minutes to contribute to the world’s largest drug survey www.globaldrugsurvey.com/GDS2018 Prof Adam Winstock is founder and CEO of GDS, consultant psychiatrist and addiction medicine specialist, GDS2018 #KnowYourDrugs December/January 2018 | drinkanddrugsnews | 17